 |
 |
News Search |
 |
 |
 |
Mutant AβPP Retards Growth in Hippocampus before Plaques Form
|
 |
 |
|
 |
 |
22 January 2003. In this week's early online edition of PNAS, collaborative research directed by Floyd E. Bloom of Neurome Inc. and the Scripps Research Institute, both in La Jolla, California, shows that dramatic changes occur in the brains of mice expressing mutant human forms of AβPP long before any Aβ has been deposited. This study is the latest in an ongoing trend pointing to damage in young adult AD mouse models prior to amyloid plaque formation, fed to date primarily by electrophysiological and behavioral tests. It is also the first report of the use of quantitative three-dimensional MRI in an AD mouse model.
First author Jeffrey Redwine et al. examined mice expressing a mutant human AβPP originally found in cases of familial AD. Using high-resolution magnetic resonance microscopy, Redwine et al. measured the volume of different regions of mouse brains at various stages of growth. At 40 days of age, the authors found no difference between wildtype mice and their transgenic littermates, indicating that embryonic and early postnatal development are unaffected by mutant APP overexpression. Already by 100 days (i.e., young adulthood), however, the transgenic mice had a 12 percent reduction in hippocampal volume. The authors found this reduction to persist unchanged until 21 months. Intriguingly, it appears to result from poorer hippocampal growth because the hippocampi in wildtype mice actually grew by about 18 percent between 40 days and 21 months. There was no growth difference between wildtype and transgenic cerebellums, but the corpus callosum was about 25 percent shorter in transgenic mice of all ages.
The stunted hippocampal growth was most evident in the molecular layer of the dentate gyrus, the projection area of the perforant pathway that is severely affected early on in human AD. The researchers could not distinguish whether the loss in the dentate gyrus results from loss of projection neurons or resident dendrites, or both.
One surprise of this study was that the hippocampus apparently continues to grow in normal adult mice. Another was that volumetric losses in the transgenic animals preceded any detectable deposition of Aβ. This leads Redwine et al. to speculate that the mutant AβPP may cause early pathologic changes that slow down normal growth of the hippocampus. Among possible culprits, the authors mention increased soluble Aβ, citing its reported ability to bind to neuronal receptors and to agrin, a protein known to function in dendritic growth and synapse formation. Finally, the authors write that their findings reinforce the importance of developing strategies to detect AD early; one of the promising candidates for this goal is measuring the volume of the hippocampus and other selected brain regions by MRI. This study also suggests that prospective imaging studies of FAD family members even in their twenties may yield valuable insight into the natural history of this disease.-Tom Fagan and Gabrielle Strobel.
Reference:
Redwine JM, Kosofsky B, Jacobs RE, Games D, Reilly JF, Morrison JH, Young WG, Bloom FE. Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. PNAS 2002 January 20.Abstract
|
 |
 |
 |
Comments on News and Primary Papers |
 |
 |
|
Comment by: Mark Mattson, ARF Advisor
|
 |
 |
Submitted 23 January 2003
|
Posted 23 January 2003
|
 |
 |
The quantitative analyses of volumes of different brain structures in an APP mutant mouse line by Redwine et al. provide valuable new information concerning the possible relationships between altered APP processing, amyloid deposition, and cellular damage in Alzheimer's disease. The data reveal reductions in the size of the hippocampal dentate gyrus and the corpus callosum that occur prior to evidence of amyloid deposits.
Indeed, both of these brain structures are smaller in the APP mutant mice as early as 40 days of age with further divergence from age-matched non-transgenic control mice at 100 days of age. Previous studies of this line of APP mutant mice have suggested no cell loss in the hippocampus, although numbers of dentate granule cells have not been quantified in a rigorous manner. However, there are data suggesting that numbers of synapses are decreased in APP mutant mice. It will be important to establish that similar decreases in the sizes of the dentate gyrus and corpus callosum occur in other lines of APP mutant transgenic mice, and to determine whether the...
Read more
View all comments by Mark Mattson
|
 |
|
|
Comment by: Paul Coleman, ARF Advisor
|
 |
 |
Submitted 28 January 2003
|
Posted 28 January 2003
|
 |
 |
This study by Redwine and colleagues is very well done and meticulous. It convincingly demonstrates reduced volume of the dentate gyrus by 100 days of age in the PDAPP transgenic mouse model of Alzheimer’s disease. Aβ-containing plaques have been shown to accumulate in this model by 240-300 days. Thus, this paper is crucial in demonstrating a frank, fairly gross structural change well in advance of the appearance of one of the major traditional markers of AD pathology.
It is important to note that two independent methods were used and that they both arrived at similar conclusions. Meticulous magnetic resonance microscopy (MRM) was used (T2 images, 11.7 T equipment) to determine the volumes of the total brain, hippocampus and cerebellum. Genu–splenium length of the corpus callosum was also measured. Ages studied were 40 days, 100 days, and 12 and 21 months. MRM data were obtained from perfusion-fixed mouse brains while still in the skull. Brain was then removed, sectioned at 50µm, and stained with thionin and cresyl violet. These stained sections were used to obtain...
Read more
View all comments by Paul Coleman
|
 |
|
|
Comment by: Scott Small
|
 |
 |
Submitted 5 February 2003
|
Posted 5 February 2003
|
 |
 |
When introduced as a clinical tool in the 1980s, MRI transformed the field of clinical neuroscience. Visualizing the brain with exquisite anatomical resolution was one thing, but to accomplish this feat noninvasively, so that human subjects could be imaged repeatedly over time, was too good to be true. Finally, we had a technique allowing us to study the natural course of disease in living patients. Up to that point, we’d relied mainly on dead human tissue, or if we wanted to study disease in a living system, we turned to animal models and used invasive mapping techniques. In a perfect illustration of science’s dialectical course, the current study—which is as powerful as it is elegant—shows that MRI’s utility can be retrofitted to the study of dead mice.
Why so much excitement over this seemingly retrogressive trend? One reason is that after a few decades of perfecting imaging protocols designed to highlight different aspects of brain anatomy and function, we now need to verify what it is we are actually imaging. Verification is best accomplished in animal...
Read more
View all comments by Scott Small
|
 |
|
|
Comment by: Gunnar Gouras, ARF Advisor
|
 |
 |
Submitted 10 February 2003
|
Posted 10 February 2003
|
 |
 |
The study by Redwine et al. provides important new evidence for FAD mutant AβPP and/or elevated Aβ causing preplaque structural changes in a well-established FAD transgenic mouse strain. The excellent comments on this paper reinforce the point that the study of how mutant APP/Aβ may relate to synaptic dysfunction and selective regional volume loss in brain certainly is an important area of study. A major question is how AβPP or Aβ is responsible for these changes. Increasing evidence favors a role for soluble Aβ oligomers in this pathological process (multiple studies; i.e., Walsh et al., 2002). Increasing evidence also indicates that preplaque Aβ accumulation occurs within nerve cells in FAD transgenic mice and AD brain (also, multiple studies, most recently Shie et al., 2003; see ARF online discussion). The biological interactions of these...
Read more
View all comments by Gunnar Gouras
|
 |
|
|
Primary Papers: Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis.
Comment by: Todd Golde, ARF Advisor
|
 |
 |
Submitted 17 February 2003
|
Posted 17 February 2003
|
 |
 |
I recommend this paper
The is an interesting and somewhat unexpected finding. At 100 days of age PDAPP mice show a small but significant decrease in hippocampal volume (12.3%). This is before there is measurable biochemical or immunohistochemical Abeta deposition. The main quesiton raised by this study is whether the change is due to APP, soluble Abeta, or even non-specific transgene effects. Further studies will be needed to sort out these possibilities.
View all comments by Todd Golde
|
 |
 |
 |
Comments on Related News |
 |
 |
|
Related News: Amyloid Ligand Looks Suited for Future Diagnostic Test
Comment by: Thomas Wisniewski
|
 |
 |
Submitted 26 September 2003
|
Posted 26 September 2003
|
 |
 |
I think this is an excellent and exciting paper. Hopefully, direct imaging of AD pathology is just around the corner for patients. The compounds developed by Dr. Klunk and used by Dr. Hyman work extremely well for in-vivo two-photon work, and show promise in human PET studies. Up to now, imaging studies of AD pathology have used indirect methods that correlate various changes (entorhinal cortex volumes, 2DG-PET, etc.) to lesions. However, the development of methodologies that directly image lesions will be an important advance for both diagnosis and early treatment. We are working on developing ligands that could be used with magnetic resonance imaging, which has a better resolution than PET (see Wadghiri et al., 2003), and these methods also show promise.
View all comments by Thomas Wisniewski
|
 |
|
|
Related News: Amyloid Ligand Looks Suited for Future Diagnostic Test
Comment by: Michael Weiner
|
 |
 |
Submitted 29 September 2003
|
Posted 29 September 2003
|
 |
 |
This is an extremely exciting paper, which reports outstanding work from the group of investigators in Pittsburgh and their collaborators around the world. There is considerable evidence that the protein called amyloid may play an important role in the development of Alzheimer's disease. The results shown in this paper are a major step forward in the development of tools to image amyloid in the human brain.
The authors should be commended for their very careful step-by-step approach to the problem. Although considerably more work needs to be done in this area, this work is extremely promising for the development of a tool which could be used for diagnosis, monitoring the effects of treatment, and even possibly early detection of Alzheimer's disease.
View all comments by Michael Weiner
|
 |
 |
 |
| |
Submit a Comment on this News Article |
 |
 |
 |
 |
|
|
|
 |